FRI0611ACUTE AND LONG-TERM EFFICACY OF IL-1 INHIBITOR ANAKINRA IN IDIOPATHIC AND SECONDARY PERICARDITIS IN PATIENTS REFRACTORY OR INTOLERANT TO CONVENTIONAL THERAPYBackground In contrast to its use in idiopathic recurrent pericarditis (IRP), efficacy and optimal treatment duration of Anakinra are unclear...
J. et al. Inflammation in human brain injury: intracerebral concentrations of IL-1α, IL-1β, and their endogenous inhibitor IL-1ra. J. Neurotrauma 24, 1545–1557 (2007). Article PubMed Google Scholar Olofsson, P. S. et al. A functional interleukin-1 receptor antagonist polymorphism ...
Some studies also suggest that IL-1 inhibitor treatment may reduce the risk of macrovascular and microvascular complications of diabetes [95,96]. IL-1 receptor antagonist Anakinra and monoclonal antibody-mediated suppression of IL-1β with canakinumab had similar effects in other trials [16,97,98]...
Interestingly, in the docetaxel control arm both the PFS (4.2 months) and OS (11.3 months) were higher than historical results obtained in the pre-immunotherapy era [153], [154], [155]) and might be an indication of the continuing effects of checkpoint inhibitor therapy received in the ...
Terkeltaub, R.et al. Placebo-controlled pilot study of Rilonacept (IL-1 trap), a long acting IL-1 inhibitor, in refractory chronic active gouty arthritis [abstract LB518-L2].Arthritis Rheum.56, 4231–4232 (2007). Google Scholar Picco, P.et al. Successful treatment of idiopathic recurrent ...
the P38 specific pathway inhibitor SB203580 (10 μM, MCE, China), the JNK specific pathway inhibitor SP600125 (10 μM, MCE, China), the AKT specific inhibitor LY294002 (10 μM, Selleckchem, USA), or the NFκB specific inhibitor Bay11−7082 (2 μM, MCE, China) for 60 min before...
We hypothesize that patients on IL-1 inhibitor show a better improvement of LGE on CMR in recurrent pericarditis.Methods: This is a retrospective comparative cohort study of 37 recurrent pericarditis patients on IL-1 inhibitor and 107 recurrent pericarditis patients on standard anti-inflammatory therapy...
A subsequent international multicenter registry of anakinra in recurrent pericarditis, the IRAP registry (International Registry of Anakinra for Pericarditis), confirmed the findings of the AIRTRIP trial in a real-world population [141]. On these bases, anakinra is currently the treatment of choice ...
IL-1Ra is a naturally occurring inhibitor of the IL-1 system. It is produced as four different isoforms derived from alternative mRNA splicing and alternative translation initiation. A 17 kDa secreted isoform of IL-1Ra is expressed as variably glycosylated species, of 22-25 Kda (9,10) now ...
Recurrent pericarditis (RP) occurs in 15 to 30% of patients following a first episode, despite standard treatment with nonsteroidal anti-inflammatory drugs, colchicine, and corticosteroids; many patients become dependent on corticosteroids. Rilonacept (KPL-914), an interleukin-1α and β inhibitor, ...